Evidence map›Paper›PMID 39575880›Full record

ArticleInternational journal of urology : official journal of the Japanese Urological Association2025

Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.

Satoru Taguchi, Taketo Kawai, Yoshiki Ambe, Kenjiro Kishitani, Michio Noda, Tomoyuki Kaneko, Jimpei Miyakawa, Yu Nakamura, Hayato Hoshina, Daisuke Obinata and 28 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of urology : official journal of the Japanese Urological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Satoru TaguchiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1291-4294
Taketo KawaiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7279-2874
Yoshiki AmbeDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Kenjiro KishitaniDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Michio NodaDepartment of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
Tomoyuki KanekoDepartment of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5762-7563
Jimpei MiyakawaDepartment of Urology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
Yu NakamuraDepartment of Urology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
Hayato HoshinaDepartment of Urology, Jichi Medical University, Shimotsuke, Tochigi, Japan.ORCID https://orcid.org/0009-0009-5067-0241
Daisuke ObinataDepartment of Urology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0002-8584-4506
Kenya YamaguchiDepartment of Urology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8632-4169
Shigenori KakutaniDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Yoshitsune FuruyaDepartment of Urology, The Fraternity Memorial Hospital, Sumida-ku, Tokyo, Japan.
Yujiro SatoDepartment of Urology, The Fraternity Memorial Hospital, Sumida-ku, Tokyo, Japan.
Yume AdachiDepartment of Urology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan.
Kazuma SugimotoDepartment of Urology, Center Hospital of the National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
Keigo SatoDepartment of Urology, Center Hospital of the National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
Mariko TabataDepartment of Urology, The Institute of Medical Science, The University of Tokyo, Minato-Ku, Tokyo, Japan.
Takehiro TanakaDepartment of Pharmacy, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
Katsuhiko NaraDepartment of Pharmacy, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
Yukari UemuraBiostatistics Section, Department of Data Science, Center of Clinical Sciences, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
Jun KameiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Yoshiyuki AkiyamaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Yusuke SatoDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Yuta YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9698-4301
Aya NiimiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4828-7851
Daisuke YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Tappei TakadaDepartment of Pharmacy, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
Sayuri TakahashiDepartment of Urology, The Institute of Medical Science, The University of Tokyo, Minato-Ku, Tokyo, Japan.
Yukio YamadaDepartment of Urology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan.
Hideyo MiyazakiDepartment of Urology, Center Hospital of the National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
Yutaka EnomotoDivision of Urology, Mitsui Memorial Hospital, Chiyoda-ku, Tokyo, Japan.
Hiroaki NishimatsuDepartment of Urology, The Fraternity Memorial Hospital, Sumida-ku, Tokyo, Japan.
Tetsuya FujimuraDepartment of Urology, Jichi Medical University, Shimotsuke, Tochigi, Japan.ORCID https://orcid.org/0000-0002-3421-8273
Hiroshi FukuharaDepartment of Urology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
Tohru NakagawaDepartment of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
Satoru TakahashiDepartment of Urology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0819-9478
Haruki KumeDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile the occurrence of immune-related adverse events has been recognized as a prognostic marker in patients receiving immune checkpoint inhibitors, the prognostic significance of treatment-related adverse events (trAEs) in patients undergoing antibody-drug conjugates such as enfortumab vedotin (EV) is controversial.

methodsWe reviewed 106 patients with advanced urothelial carcinoma who were treated with EV therapy at 10 institutions between 2021 and 2023. Associations of clinical parameters with overall survival and progression-free survival were assessed using the Cox proportional hazards model. For the assessment of trAEs, landmark analysis was conducted to minimize immortal time bias.

resultsOf 106 patients, 55 (51.9%) experienced disease progression and 44 (41.5%) died during the follow-up period. Any grade and grade ≥3 trAEs occurred in 94 (88.7%) and 44 (41.5%) patients, respectively. Common trAEs included skin disorders (74.5%), gastrointestinal disorders (62.3%), fatigue (50.0%), peripheral neuropathy (36.8%), and hematological disorders (37.7%). One patient died of interstitial pneumonia (grade 5). According to landmark analysis using 88 patients who survived for 2 months or more, trAEs were significantly associated with longer survival. Furthermore, when trAEs were classified into "physical trAEs" such as skin disorders and "laboratory trAEs" such as hematological disorders, the former were associated with longer survival while the latter were associated with shorter survival.

conclusionsPhysical, but not laboratory, trAEs are associated with favorable outcomes of EV therapy for advanced urothelial carcinoma. Both managing trAEs and utilizing them as prognostic markers are key points in the use of antibody-drug conjugates such as EV.

Indexed as

Antibodies, MonoclonalCarcinoma, Transitional CellImmune Checkpoint InhibitorsImmunoconjugatesUrinary Bladder NeoplasmsAgedAged, 80 and overDisease ProgressionFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesTreatment OutcomeAntibodies, Monoclonalenfortumab vedotinImmune Checkpoint InhibitorsImmunoconjugatesadverse eventenfortumab vedotinimmortal time biaslandmark analysisurothelial carcinoma

Identifiers

PMID39575880
PMCPMC11923521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.